NASDAQ
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
♥ 574 Thanks from members
Ironwood Pharmaceuticals (IRWD) trades at a significant discount despite strong Q2 2026 profitability, raised guidance, and double-digit LINZESS growth. However, investors face a severe binary risk and impending 2029 generic cliff tied to its pipeline transition toward apraglutide.